Mylan announced yesterday that Didier Barret, president of Mylan Europe, Middle East and Africa (EMEA), has been elected president of the European Generic Medicines Association (EGA). The EGA represents the European generic and bio-similar pharmaceutical industry

Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan SA has received the prestigious 2009 Elsevier Galien Award for Best Generics Company in Spain. The award recognizes the company’s outstanding development in the country during the last year and its introduction of new, high quality generic medicines that generate savings for the national health care system.

President Clinton and Mylan Chairman and CEO Robert J. Coury Announce New Agreement to Lower Price of Treatment for Patients with Drug-Resistant HIV in Developing Countries.
"Second-line" HIV/AIDS treatment available from Matrix, a Mylan company, at $475 today and at $425 in 2010, 28% lower than the current lowest-priced alternative."

Mylan Inc. (Nasdaq: MYL) today announced that it has executed a definitive agreement with Biocon Limited, a publicly traded company on the Indian stock exchanges, for an exclusive collaboration on the development, manufacturing, supply and commercialization of multiple, high value generic biologic compounds for the global marketplace.

Mylan Inc. (Nasdaq: MYL) today announced that its wholly-owned subsidiary, MP Laboratories (Mauritius) Ltd, has completed its delisting offer for the publicly held shares of Matrix Laboratories Limited, the world's third largest active pharmaceutical ingredient manufacturer in which Mylan acquired a controlling interest in 2007